axicabtagene ciloleucel + atezolizumab

**Axicabtagene ciloleucel + atezolizumab** is an experimental combination therapy evaluated for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Axicabtagene ciloleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, while atezolizumab is a monoclonal antibody immune checkpoint inhibitor targeting programmed death-ligand 1 (PD-L1). Axicabtagene ciloleucel is designed to genetically engineer a patient's T cells to express a CAR targeting the CD19 antigen on B cells, resulting in T cell activation, proliferation, and targeted cytotoxicity against CD19-expressing lymphoma cells. Atezolizumab blocks the interaction between PD-L1 and its receptors PD-1 and B7.1, thereby enhancing T-cell antitumor activity by preventing T-cell exhaustion. The combination aims to improve antitumor immune activity by combining CAR T-cell cytotoxicity with immune checkpoint inhibition to mitigate tumor immune evasion. This combination has primarily been investigated in the ZUMA-6 phase I/II clinical trial for advanced DLBCL[3][5].

Other names

axi-cel + atezolizumab